Etavopivat is under clinical development by Forma Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II drugs for Anemia have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Etavopivat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Etavopivat overview

Etavopivat (FT-4202) is under development for the treatment of sickle cell disease, beta thalassemia and anemia with low risk myelodysplastic syndrome. The drug candidate is administered through oral route as tablet. It acts by targeting pyruvate kinase (PKR) enzyme.

Forma Therapeutics overview

Forma Therapeutics (Forma) is a biotech company. It develops technologies to identify the initial molecules that provide drug discovery program. It offers research in the areas of tumor metabolism, protein homeostasis, epigenetics, and protein-protein interactions. FORMA’s drug development process includes computational and medicinal chemistry, parallel synthesis, X-ray crystallography, and relevant biology studies. The company collaborates with biotechnology companies, pharmaceuticals and biomedicine companies and research institutes for its research and development activities. It operates offices in Watertown and Branford, the US. FORMA is headquartered in Watertown, Massachusetts, the US.

For a complete picture of Etavopivat’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.